恶性黑色素瘤化疗研究进展

doi:10.11904/j.issn.1002-3070.2019.02.013

Abstract

Abstract: Malignant melanoma(MM)is a very malignant solid tumor that is highly invasive and has a poor prognosis.Although the treatment of advanced melanoma has entered the era of targeting and immunotherapy,chemotherapy is still not to be abandoned.Chemotherapy for malignant melanoma has undergone a development process from single-drug chemotherapy,combination of two or three or even four drugs,and biochemotherapy.This article reviews the progress of chemotherapy for malignant melanoma,compares the main chemotherapy regimens,and looks forward into the future direction of chemotherapy.

Key words: Malignant melanoma, Chemotherapy, Biochemotherapy, Targeting therapy

CLC Number:

R739.5

QIN Lanqun, ZOU Zhengyun. Progress in chemotherapy for malignant melanoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 167-172.

References

1 Eggermont AM,Spatz A,Robert C.Cutaneous melanoma[J].Lancet,2014,383(9919):816-827.
2 Gupta A,Gomes F,Lorigan P.The role for chemotherapy in the modern management of melanoma[J].Melanoma Management,2017,4(2):125-136.
3 Middleton M,Grob J,Aaronson N,et al.Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma[J].J Clin Oncol,2000,18(1):158-166.
4 Avril MF,Aamdal S,Grob JJ,et al.Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:a phase III study[J].J Clin Oncol,2004,22(6):1118-1125.
5 Teimouri F,Nikfar S,Abdollahi M.Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma:a meta-analysis consisting of 1314 patients[J].Melanoma Res,2013,23(5):381-389.
6 Yardley DA.Nab-paclitaxel mechanisms of action and delivery[J].J Control Release,2013,170(3):365-372.
7 Ibrahim NK,Desai N,Legha S,et al.Phase I and pharmacokinetic study of ABI-007,a Cremophor-free,protein-stabilized,nanoparticle formulation of paclitaxel[J].Clin Cancer Res,2002,8(5):1038-1044.
8 Hersh EM,Del Vecchio M,Brown MP,et al.A randomized,controlled phase Ⅲ trial of nab-Paclitaxel versus dacarbazine in chemotherapy-nave patients with metastatic melanoma[J].Ann Oncol,2015,26(11):2267-2274.
9 Tomi＇c K,Tica Sedlar I,Beri＇c Jozi＇c G,et al.Complete response of metaststic melanoma to second line chemotherapy with paclitaxel and carboplatin[J].Acta Med Acad,2018,47(1):82-87.
10 Lee CK,Jung M,Choi HJ,et al.Results of a phase Ⅱ study to evaluate the efficacy of docetaxel and carboplatin in metastatic malignant melanoma patients who failed first-line therapy containing dacarbazine[J].Cancer Res Treat,2015,47(4):781-789.
11 Kottschade LA,Suman VJ,Amatruda T,et al.A phase II trial of nab-paclitaxel(ABI-007)and carboplatin in patients with unresectable stage IV melanoma:a North Central Cancer Treatment Group Study,N057E(1)[J].Cancer,2011,117(8):1704-1710.
12 Guo YQ,Ding Y,Li DD,et al.Efficacy and safety of nab-paclitaxel combined with carboplatin in chinese patients with melanoma[J].Med Oncol,2015,32(9):234.
13 Dalgleish AG.Rational for combining immunotherapy with chemotherapy[J].Immunotherapy,2015,7(3):309-316.
14 Buzaid AC.Biochemotherapy for advanced melanoma[J].Crit Rev Oncol Hematol,2002,44(1):103-108.
15 Eton O,Legha SS,Bedikian AY,et al.Sequential biochemotherapy versus chemotherapy for metastatic melanoma:results from a phase III randomized trial[J].J Clin Oncol,2002,20(8):2045-2052.
16 Atkins MB,Hsu J,Lee S,et al.Phase III trial comparing concurrent biochemotherapy with cisplatin,vinblastine,dacarbazine,interleukin-2,and interferon alfa-2b with cisplatin,vinblastine,and dacarbazine alone in patients with metastatic malignant melanoma(E3695):a trial coordinated by the Eastern Cooperative Oncology Group[J].J Clin Oncol,2008,26(35):5748-5754.
17 Flaherty LE,Othus M,Atkins MB,et al.Southwest Oncology Group S0008:a phase III trial of high-dose interferon Alfa-2b versus cisplatin,vinblastine,and dacarbazine,plus interleukin-2 and interferon in patients with high-risk melanoma-an intergroup study of cancer and leukemia Group B,Children's Oncology Group,Eastern Cooperative Oncology Group,and Southwest Oncology Group[J].J Clin Oncol,2014,32(33):3771-3778.
18 Alrwas A,Papadopoulos NE,Cain S,et al.Phase I trial of biochemotherapy with cisplatin,temozolomide,and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma[J].Melanoma Res,2014,24(4):342-348.
19 Robert C,Schachter J,Long GV,et al.Pembrolizumab versus ipilimumab in advanced melanoma[J].N Engl J Med,2015,372(26):2521-2532.
20 Robert C,Thomas L,Bondarenko I,et al.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J].N Engl J Med,2011,364(26):2517-2526.
21 Patel SP,Kim DW,Bassett RL,et al.A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma[J].Cancer Immunol immunother,2017,66(10):1359-1366.
22 Maio M,Grob J,Aamdal S,et al.Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial[J].J Clin Oncol,2015,33(10):1191-1196.
23 Yamazaki N,Uhara H,Fukushima S,et al.Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated,unresectable or metastatic melanoma[J].Cancer Chemother Pharmacol,2015,76(5):969-975.
24 Funazumi M,Namiki T,Arima Y,et al.Increased infiltration of CD8⁺T cells by dacarbazine in a patient with mucosal penile melanoma refractory to nivolumab[J].Ann Dermatol,2016,28(4):486-490.
25 Kim KB,Sosman JA,Fruehauf JP,et al.BEAM:a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma[J].J Clin Oncol,2012,30(1):34-41.
26 Von Moos R,Seifert B,Simcock M,et al.First-line temozolomide combined with bevacizumab in metastatic melanoma:a multicentre phase II trial(SAKK 50/07)[J].Ann Oncol,2012,23(2):531-536.
27 Ferrucci PF,Minchella I,Mosconi M,et al.Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma[J].Melanoma Res,2015,25(3):239-245.
28 Cui C,Mao L,Chi Z,et al.A phase II,randomized,double-blind,placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma[J].Mol Ther,2013,21(7):1456-1463.
29 Flaherty KT,Puzanov I,Kim KB,et al.Inhibition of mutated,activated BRAF in metastatic melanoma[J].N Engl J Med,2010,363(9):809-819.
30 Si L,Kong Y,Xu X,et al.Prevalence of BRAF V600E mutation in Chinese melanoma patients:large scale analysis of BRAF and NRAS mutations in a 432-case cohort[J].Eur J Cancer,2012,48(1):94-100.
31 Robert C,Dummer R,Gutzmer R,et al.Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma:a phase 2 double-blind randomised study[J].Lancet Oncol,2013,14(8):733-740.
32 Queirolo P,Spagnolo F,Picasso V,et al.Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib[J].Oncotarget,2016,9(15):12408-12417.
33 Rangwala R,Leone R,Chang YC,et al.Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma[J].Autophagy,2014,10(8):1369-1379.
34 Xia C,Leon-Ferre R,Laux D,et al.Treatment of resistant metastatic melanoma using sequential epigenetic therapy(decitabine and panobinostat)combined with chemotherapy(temozolomide)[J].Cancer Chemother Pharmacol,2014,74(4):691-697.
35 Hong DS,Kurzrock R,Falchook GS,et al.Phase 1b study of lenvatinib(E7080)in combination with temozolomide for treatment of advanced melanoma[J].Oncotarget,2015,6(40):43127-43134.
36 Fukuda K,Funakoshi T,Sakurai T,et al.Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma[J].Melanoma Res,2017,27(4):326-334.
37 Dronca RS,Allred JB,Perez DG,et al.Phase II study of temozolomide(TMZ)and everolimus(RAD001)therapy for metastatic melanoma[J].Am J Clin Oncol,2014,37(4):369-376.
38 Middleton MR,Friedlander P,Hamid O,et al.Randomized phase II study evaluating veliparib(ABT-888)with temozolomide in patients with metastatic melanoma[J].Ann Oncol,2015,26(10):2173-2179.
39 Carvajal RD,Wong MK,Thompson JA,et al.A phase 2 randomised study of ramucirumab(IMC-1121B)with or without dacarbazine in patients with metastatic melanoma[J].Eur J Cancer,2014,50(12):2099-2107.
40 Bedikian AY,Garbe C,Conry R,et al.Dacarbazine with or without oblimersen(a Bcl-2 antisense oligonucleotide)in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase[J].Melanoma Res,2014,24(3):237-243.

[1]	LIANG Hong, LI Qi, WANG Yaoxian, JIN Hong, WANG Tong, WANG Yanan, DUAN Yani, SONG Min. Interrupted time series trial for prevention of cardiovascular toxicity induced by chemotherapy in cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 134-138.
[2]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[3]	CHANG Xiaoxia, SONG Bingbing, LIU Jiaren. Research progress in phytochemicals for increasing sensitivity of tumor cells to chemotherapies [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 67-72.
[4]	JIANG Liangliang, WANG Jing. Progress in diagnosis and treatment of distant metastasis of epithelial ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 480-482.
[5]	LIU Yajing, LIU Guoyu, WANG Shubin, FANG Zhengyu. Effect of salinomycin on proliferation and autophagic flow of human malignant melanoma M21 cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 203-207.
[6]	ZHANG Ting, JIA Di, YANG Dan. Progress in biological treatment of osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 254-257.
[7]	ZHAI Keke, GAO Yuanyuan, FENG Xiao, XU Jingwen, GONG Yufang, MENG Qingwei. Analysis of first-line NSCLC chemotherapy in the phase Ⅳ patients with distant metastasis and first diagnosis after postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 107-111.
[8]	YANG Wenjuan, YU Jing, HUANG Zhao, ZHANG Junhong, XIE Conghua. Correlation between the decline of severe granulocyte in the early stage of chemotherapy and the prognosis of small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 19-24.
[9]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[10]	LIANG Yusi, TAN Yonggang, ZOU Huawei. Research progress on mechanism of low-dose chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 538-542.
[11]	DONG Feng,MA Junjun,CAI Zhenghao,ZHAO Xuan,ZHENG Minhua. The correlation between serum miR-21 and miR-34a expression and the efficacy of Flofox chemotherapy regimen in patients with advanced gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 147-151.
[12]	CHEN Li, ZHANG Yuxin, ZUO Yanjiao, MA Fei, SONG Hongjiang, XUE Yingwei. The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 23-30.
[13]	ZHANG Rui,WANG Zhiyu,WANG Shuai,ZHAO Hui. Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diagnosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 527-522.
[14]	SUN Dawei,LEI Minghui. The study on immunity and tumor recurrence of oral cancer patients with the combination therapy of hyperbaric oxygen treatment and postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 533-537.
[15]	REN Tingting,XING Ying,MENG Qingwei. Progress in association between autophagy and cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 543-546.

Progress in chemotherapy for malignant melanoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments